Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide Compared With Placebo in Adult Participants With Major Depressive Disorder Who Have Partial Response to Antidepressant Therapy (RENEW-MDD-3)

NCT07928245 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07928245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide Compared With Placebo in Adult Participants With Major Depressive Disorder Who Have Partial Response to Antidepressant Therapy (RENEW-MDD-3)
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
July 31, 2028
Enrollment
330 (estimated)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Brenipatide ExperimentalBrenipatide

    Brenipatide administered subcutaneously (SC) + standard of care (SoC) anti-depressant

  • Placebo Placebo comparatorPlacebo

    Placebo administered SC + SoC anti-depressant

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS-9) Score Baseline, Week 10

Lead sponsor's other trials

Eli Lilly and Company, most recent start first.

Similar trials

Same condition (Major Depressive Disorder) and phase, most recent start first.